Daniel E.
- Country
- Austria
- Department
- University Clinic for gynaecology and obstetrics
Research Overview
- Comparison of Adjuvant Elacestrant with Standard Endocrine Therapy in High-Risk ER+/HER2- Early Breast Cancer
- Phase 3 Randomized Study of Gedatolisib Combination Therapy versus Standard Endocrine Therapy in HR‑Positive, HER2‑Negative Advanced Breast Cancer Post‑CDK4/6 Inhibitor
- Efficacy and Safety of Giredestrant vs. Fulvestrant with CDK4/6 Inhibitor in ER+ HER2- Advanced Breast Cancer Resistant to Endocrine Therapy
Data & Insights
Has run more than one trial at 507 of 816 partner sites.
Specializations
Ovarian Cancer Research
Specializes in investigating novel therapeutic approaches for epithelial ovarian cancer, with particular focus on maintenance therapies following standard treatments.
- Advanced Stage Treatment
- FOLR1-expressing Ovarian Cancer
- Platinum-Resistant Disease
Explores innovative combinations including aromatase inhibitors, PARP inhibitors, and immunotherapy agents for ovarian cancer management.
Endometrial Cancer Studies
Conducts research in advanced and recurrent endometrial cancer treatment strategies, incorporating targeted and immunotherapy approaches.
- Maintenance Therapy Development
- High-Risk Disease Management
- Post-Immunotherapy Treatment
Investigates combination therapies including targeted agents and immunotherapeutics for various stages of endometrial cancer.
Cervical Cancer Expertise
Focuses on treatment approaches for locally advanced cervical cancer and metastatic disease states.
- Chemoradiotherapy Protocols
- Second-line Treatment Strategies
- Recurrent Disease Management
Evaluates novel therapeutic combinations including immunotherapy agents for improved patient outcomes in cervical cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.